GlassScriptPhysician profile
Ada Rose Edwards
NPI 1053869073
$4,735.80
in general payments reported to CMS, 2019-2025
32 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $296 · 2022: $1,200 · 2023: $697 · 2024: $1,052 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $484.60 | 2022-2025 | |
| Biotronik Nro, INC. | $320.96 | 2025 | Prospera |
| Genzyme Corporation | $303.86 | 2023-2024 | |
| Nevro Corp. | $296.14 | 2021 | |
| Saluda Medical Americas, INC. | $294.22 | 2022-2025 | Evoke |
| Mml US, INC. | $201.42 | 2024 | Reactiv8 |
| Ultragenyx Pharmaceutical INC. | $186.72 | 2022-2023 | Crysvita |
| Axsome Therapeutics, INC. | $179.15 | 2025 | Symbravo |
| Pfizer INC. | $173.43 | 2025 | |
| Inspire Medical Systems, INC. | $129.69 | 2025 | Inspire |
| Neurelis, INC. | $126.82 | 2024 | Valtoco |
| Pharmaessentia USA Corporation | $125.00 | 2022 | |
| Exact Sciences Corporation | $124.03 | 2023 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $123.96 | 2024 | Inpefa |
| Abbott Laboratories | $121.94 | 2022-2024 | Proclaim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $121.82 | 2025 | Vyvgart |
| Sage Therapeutics, LLC | $117.86 | 2023 | |
| Amarin Pharma, INC. | $117.78 | 2025 | Vascepa |
| Grt US Holding, INC. | $114.72 | 2022 | |
| Glaxosmithkline, LLC. | $113.54 | 2022 | |
| Gilead Sciences, INC. | $113.23 | 2023 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.83 | 2022 | |
| Bioventus LLC | $102.94 | 2022 | |
| Hologic Sales and Service, LLC | $99.63 | 2024 | Aptima |
| Tonix Medicines, INC. | $94.25 | 2025 | Tonmya |
| Scynexis, INC. | $88.48 | 2022 | |
| Ucb, INC. | $87.55 | 2022 | |
| Amgen INC. | $85.22 | 2025 | Krystexxa |
| Spr Therapeutics, INC | $65.00 | 2023 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.11 | 2025 | Relistor |
| Boston Scientific Corporation | $31.17 | 2024 | |
| Tersera Therapeutics LLC | $29.73 | 2024 | Prialt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ada Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.